RxDoctor Payments Data

Irena Gesheva, MD

Family Medicine · Port Charlotte, FLNPI 1326122508

Payments from drug & device makers

$4,967in general payments, 2019–2025

Across 248 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$576
  • Boston Scientific$337
  • Novo Nordisk$311
  • Amgen$291
  • Bayer$271
  • Johnson & Johnson$252
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$4,957100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,967 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$346,594
Medicare patients
492
Services billed
8,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$236,564
MounjaroTirzepatide117$201,257
EliquisApixaban85$117,372
JardianceEmpagliflozin87$101,838
RybelsusSemaglutide38$70,577
TrulicityDulaglutide42$51,279
FarxigaDapagliflozin Propanediol39$46,934
XareltoRivaroxaban30$45,221
MyrbetriqMirabegron56$41,835
ProliaDenosumab18$31,384
JanumetSitagliptin Phos/Metformin Hcl33$30,385
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$29,519
VascepaIcosapent Ethyl34$25,660
KerendiaFinerenone22$22,350
JanuviaSitagliptin Phosphate16$21,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$311$324,743192 claims
Lilly USA, LLCMounjaro, Trulicity$214$252,536159 claims
PfizerEliquis$78$117,37285 claims
Boehringer IngelheimJardiance$120$101,83887 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$157$81,33875 claims
MerckJanumet, Januvia$45$52,35949 claims
Johnson & JohnsonXarelto$252$45,22130 claims
Astellas Pharma US IncMyrbetriq$72$41,83556 claims
AmgenProlia$291$31,38418 claims
BayerKerendia$271$22,35022 claims
GSKTrelegy Ellipta$240$21,91121 claims
AbbVieLinzess$576$10,22611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →